AstraZeneca (AZN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

US Stock MarketDetailed Quotes

AZN AstraZeneca

Watchlist

77.250
+1.150+1.51%

Close Mar 4 16:00 ET

77.653
+0.403+0.52%

Post 20:01 ET

239.50BMarket Cap34.33P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

AION Labs, In Continued Partnership With BioMed X, Launches 2025 Global Call for Applications: Generative AI for Novel Target Combinations
PR NewswireMar 4 08:00 ET
AstraZeneca (AZN) Receives a Buy From Bernstein
TipRanksMar 4 02:56 ET · Ratings
HANSOH PHARMA (03692) and other pharmaceutical companies jointly applied for the market launch of a new indication for the anti-CD19 monoclonal antibody.
On March 4, the official website of the China National Medical Products Administration announced that a new indication for the injection of Inalizumab, jointly submitted by Horizon Therapeutics, AstraZeneca (AZN.US), and HANSOH PHARMA (03692), has been accepted.
Zhitong FinanceMar 3 21:08 ET
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
BenzingaMar 3 11:49 ET
Daiichi Sankyo and AstraZeneca Report Positive Result in Trial for Its Gastric Cancer Treatment
Seeking AlphaMar 3 11:07 ET
Enhertu Releases Results In Overall Survival For HER2 Positive Metastatic Gastric Cancer In Destiny-Gastric04 Phase 3 Trial Interim Analysis
BenzingaMar 3 08:11 ET

Comments

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

$AstraZeneca (AZN.US)$
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer

ENHERTU® Recommended for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$AstraZeneca (AZN.US)$
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor

$LumiraDx (LMDXF.US)$ if we started bringing awareness to X FB and other social media platforms we could probably win this fight. I stayed in Lumiradx because I figured if $AstraZeneca (AZN.US)$ had scooped it up we would have been jipped. $ROCHE HOLDING AG (RHHBY.US)$ seemed like a better fit as they have a plethora of innovative solutions to revitalize companies. 350m seems like an $Abbott Laboratories (ABT.US)$ or $Johnson & Johnson (JNJ.US)$ move to me and I don't buy it. Not from Roche.

2

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

$Sophia Genetics (SOPH.US)$ $AstraZeneca (AZN.US)$
Global Healthcare Revolution: Elite Hospitals Rush to Implement This Game-Changing Cancer Test

Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-h

$AstraZeneca (AZN.US)$
Breakthrough in Bladder Cancer Treatment: AstraZeneca's IMFINZI Slashes Disease Progression Risk by 42%

IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-h

1

Read more